Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DVAXNASDAQ:INVANASDAQ:MNKDNASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDVAXDynavax Technologies$10.28+1.2%$10.15$9.22▼$14.63$1.23B1.032.16 million shs511,141 shsINVAInnoviva$19.20-1.0%$19.74$16.21▼$22.00$1.21B0.37696,031 shs617,656 shsMNKDMannKind$3.61-0.4%$4.25$3.52▼$7.63$1.10B0.962.43 million shs1.74 million shsXOMAXOMA Royalty$26.43+1.2%$25.23$18.35▼$35.00$316.34M0.9335,079 shs25,289 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDVAXDynavax Technologies+1.18%+3.42%+2.70%-18.74%-6.72%INVAInnoviva-1.03%-5.84%-6.80%+8.35%+17.58%MNKDMannKind-0.41%-4.38%-18.44%-23.95%-28.33%XOMAXOMA Royalty+1.24%-3.24%+8.38%+35.98%+2.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDVAXDynavax Technologies4.205 of 5 stars3.32.00.04.70.61.71.9INVAInnoviva3.9095 of 5 stars3.50.00.04.20.61.71.9MNKDMannKind2.7693 of 5 stars3.61.00.00.01.41.71.9XOMAXOMA Royalty4.4403 of 5 stars3.54.00.03.02.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDVAXDynavax Technologies 2.50Moderate Buy$24.00133.46% UpsideINVAInnoviva 3.00Buy$55.00186.46% UpsideMNKDMannKind 3.29Buy$10.33186.64% UpsideXOMAXOMA Royalty 3.00Buy$69.50162.92% UpsideCurrent Analyst Ratings BreakdownLatest XOMA, INVA, DVAX, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025XOMAXOMA RoyaltyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.005/7/2025DVAXDynavax TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.004/17/2025DVAXDynavax TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$12.00 ➝ $10.004/17/2025XOMAXOMA RoyaltyBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/10/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.004/9/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDVAXDynavax Technologies$294.62M4.19$0.16 per share64.16$4.54 per share2.26INVAInnoviva$358.71M3.36$3.39 per share5.66$11.03 per share1.74MNKDMannKind$285.50M3.84$0.14 per share26.08($0.29) per share-12.43XOMAXOMA Royalty$13.05M24.25N/AN/A$6.95 per share3.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDVAXDynavax Technologies$27.31M-$0.52N/A20.98N/A-20.39%3.59%2.20%8/5/2025 (Estimated)INVAInnoviva$23.39M-$1.01N/A12.39N/A-16.15%15.77%8.41%7/29/2025 (Estimated)MNKDMannKind$27.59M$0.1036.0515.67N/A10.12%-32.41%10.85%8/6/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.15N/AN/AN/A-13.04%-12.43%-4.85%8/12/2025 (Estimated)Latest XOMA, INVA, DVAX, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025INVAInnoviva$0.43N/AN/AN/A$87.10 millionN/A5/13/2025Q1 2025XOMAXOMA Royalty-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/6/2025Q1 2025DVAXDynavax Technologies$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDVAXDynavax TechnologiesN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDVAXDynavax Technologies0.4911.9310.84INVAInnoviva0.402.482.30MNKDMannKindN/A2.362.11XOMAXOMA Royalty1.185.545.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDVAXDynavax Technologies96.96%INVAInnoviva99.12%MNKDMannKind49.55%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipDVAXDynavax Technologies2.98%INVAInnoviva2.25%MNKDMannKind2.70%XOMAXOMA Royalty9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDVAXDynavax Technologies350120.08 million116.50 millionOptionableINVAInnoviva10062.78 million61.36 millionOptionableMNKDMannKind400303.93 million295.73 millionOptionableXOMAXOMA Royalty1011.97 million10.88 millionOptionableXOMA, INVA, DVAX, and MNKD HeadlinesRecent News About These CompaniesAcuitas Investments LLC Trims Stake in XOMA Royalty Corporation (NASDAQ:XOMA)July 2 at 9:54 AM | marketbeat.comTop biotech deals in June 2025July 2 at 9:17 AM | labiotech.euLXOMA Royalty (NASDAQ:XOMA) Downgraded to "Hold" Rating by Wall Street ZenJune 29, 2025 | americanbankingnews.comXOMA Royalty (NASDAQ:XOMA) Downgraded by Wall Street Zen to HoldJune 28, 2025 | marketbeat.comXOMA Royalty to Buy Turnstone BiologicsJune 27, 2025 | marketwatch.comTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...June 27, 2025 | gurufocus.comTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...June 27, 2025 | gurufocus.comXOMA Royalty Corporation to Acquire Turnstone Biologics Corp. in Cash and CVR Merger DealJune 27, 2025 | quiverquant.comQTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value RightJune 27, 2025 | globenewswire.comXOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?June 24, 2025 | zacks.comXOMA Royalty (NASDAQ:XOMA) Stock Crosses Above 200 Day Moving Average - Should You Sell?June 24, 2025 | marketbeat.comXOMA Preferred Shares Series A declares $0.539 dividendJune 18, 2025 | seekingalpha.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendJune 18, 2025 | seekingalpha.comXOMA Royalty Declares Quarterly Preferred Stock DividendsJune 18, 2025 | investing.comXOMA Royalty Declares Quarterly Preferred Stock DividendsJune 18, 2025 | globenewswire.comXOMA (NASDAQ:XOMA) Rating Increased to Buy at Wall Street ZenJune 14, 2025 | marketbeat.comPositive Outlook for Xoma: Strategic Positioning and Pricing Dynamics Drive Buy RatingMay 29, 2025 | tipranks.comXOMA boosts stake in anti-CD38 antibody with $30 million dealMay 28, 2025 | thepharmaletter.comTXOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)May 28, 2025 | benzinga.comXOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy RatingMay 28, 2025 | tipranks.comXOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 MillionMay 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXOMA, INVA, DVAX, and MNKD Company DescriptionsDynavax Technologies NASDAQ:DVAX$10.28 +0.12 (+1.18%) Closing price 07/3/2025 03:20 PM EasternExtended Trading$10.28 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Innoviva NASDAQ:INVA$19.20 -0.20 (-1.03%) Closing price 07/3/2025 01:23 PM EasternExtended Trading$19.20 0.00 (0.00%) As of 07/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.MannKind NASDAQ:MNKD$3.60 -0.02 (-0.41%) Closing price 07/3/2025 03:48 PM EasternExtended Trading$3.61 +0.00 (+0.14%) As of 07/3/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.XOMA Royalty NASDAQ:XOMA$26.43 +0.32 (+1.24%) As of 07/3/2025 01:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
